Zentalis Pharmaceuticals, Inc. - Common Stock (ZNTL)

CUSIP: 98943L107

Q1 2024 13F Holders as of 31 Mar 2024

Holder snapshot 7 signals
Share change
+4,205,796
Put/Call ratio
3.4%
SEC-reported price per share
$15.76
Number of holders
140
Value change
+$67,005,140
Number of buys
75
Open additional details 1 more signal available
Number of sells
49
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
94,436,195

Security key

98943L107

Report period

Q1 2024

Institutions

140

Top holders

10

Ownership snapshot

Top reported holders of ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Matrix Capital Management...
Disclosed value leader
Matrix Capital Management...
Comparable rows
0/15
Latest evidence
31 Dec 2023
13F 3/4/5 Highest disclosed value: $211,493,591 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Matrix Capital Management Company, LP has the largest disclosed position value at $211.49M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Matrix Capital Management Company, LP's linked filing trail.
Disclosed position value Top 5
Matrix Capital Management Company... $211.49M
EVENTIDE ASSET MANAGEMENT, LLC $175.13M
VANGUARD GROUP INC $81.06M
BlackRock Finance, Inc. $70.98M
STATE STREET CORP $66.92M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Matrix Capital Management Company, LP
13F
Company
13F
—
denominator unverified
$211,493,591
13,959,973 shares
— 31 Dec 2023
EVENTIDE ASSET MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$175,133,621
11,559,975 shares
— 31 Dec 2023
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$81,059,439
5,350,458 shares
— 31 Dec 2023
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$70,977,371
4,684,975 shares
— 31 Dec 2023
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$66,918,398
4,417,056 shares
— 31 Dec 2023
CITADEL ADVISORS LLC
13F
Company
13F
—
denominator unverified
$55,778,998
3,681,782 shares
— 31 Dec 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
140
Shares
85,290,558
Rows available
140
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q1 2024 Across Filers

Q1 2024 holders
140
Q1 2024 holders
140
Holder diff
0
Investor Q1 2024 Shares Q1 2024 Shares Share Diff Share Chg % Q1 2024 value Q1 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .